If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Jaypirca ™ (pirtobrutinib) tablets
50 mg,100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Has Jaypirca™ (pirtobrutinib) been studied in pediatric patients?
The safety and effectiveness of Jaypirca (pirtobrutinib) have not been established in pediatric patients.
Pirtobrutinib Use in Pediatric Patients
The safety and effectiveness of pirtobrutinib have not been established in pediatric patients.1
Enclosed Prescribing Information
1Jaypirca [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: January 09, 2023